Released on = July 3, 2006, 9:14 pm

Press Release Author = RNCOS

Industry = Industrial

Press Release Summary = With major pharmaceutical companies launching innovative &
effective products, such as non-injectable insulin, diabetics can now take a sigh of
relief from other painful options.

Press Release Body = Victimizing more than 194Mn people all over the world, diabetes
has surfaced as one of the most fatal diseases known to man. As a consequence of
growing cases of diabetes, innovative & effective therapeutic options are
desperately needed by both medical fraternity and patients.

Various pharmaceutical companies are engaged in researching and developing the most
accurate & effective therapeutic options for the disease. The latest addition to
this continuous endeavor is an innovative product by Pfizer, a leading
pharmaceutical company. Pfizer has announced that it'll launch its latest product
Exubera (inhaled insulin) in July 2006. The product will be available throughout the
United States.

"New Developments in Insulin Delivery Systems (2006)", a recently published market
research report by RNCOS, includes an in-depth analysis of every relevant issue
related to the insulin deliver systems. Not only does it provide the information on
the current developments taking place in the industry, it also includes a discussion
on the causes & symptoms of the disease.

As per the research, "About 18Mn, out of the total 165Mn diabetic patients across
the world, are in USA alone. About 5% of these patients suffer from Type 1 diabetes
(also known as "Juvenile diabetes"). Type 1 diabetes is mainly caused by the
destruction of the islet cells (insulin producing cells). However rest of them have
Type 2 diabetes, characterized by body's inability to take advantage of the insulin
that's available. The main causes of Type 2 diabetes are obesity, aging & physical
inactivity".

Main Features of the Report

§ Information about the traditional and non-traditional therapies to help in
comparative analysis of the industry.
§ Market sizing and growth rate of insulin delivery market across USA, Western
Pacific, South and Central America, Europe and Asia.
§ Analysis of the diabetes drug market across the globe.
§ Profile discussion of key players such as Eli Lilly & Company, Sanofi-Aventis,
GlaxoSmithKline plc, Novo Nordisk A/S, Amylin Pharmaceuticals etc.
§ Reliable predictions about the industry in the years to come.

About RNCOS:
RNCOS, incorporated in 2002, provides Market Research Reports for your business
needs and aims to put an end to your information pursuit. Our expertise in gathering
global business information for industry research, corporate training, growth
consulting, and business consulting, brings reputed companies and firms to us for
business enhancement solutions. We can be your one-stop-shop for Industry research
information and niche market analysis.

To purchase your copy: http://www.rncos.com/Report/IM040.htm
For more information about the report please visit www.rncos.com


Web Site = http://www.rncos.com

Contact Details = RNCOS
Shushmul Maheshwari
Head of Business Development
29, 1st Floor, Patparganj Industrial area, Delhi 92
91-11-4214-1229
info@rncos.com